drugset / Trial / NCT00028418

Clofarabine in Chronic Lymphocytic Leukemia

NCT00028418

Phase 1 Completed 100 enrolled M.D. Anderson Cancer Center
Non-randomizedOpen-labelTreatment

Summary

This is a dose-escalation study to determine the maximum tolerated dose and toxic effects of clofarabine in patients with chronic lymphocytic leukemia and other acute leukemias. Clofarabine is a synthesized hybrid nucleoside analog, which is believed to possess the better qualities of fludarabine and chlorodeoxyadenosine, the 2 most active agents against lymphoproliferative disorders. Thus, it is hoped that this drug will be more active and less toxic than similar drugs.

Timeline

Start
1999-02
Primary completion
Completion
2004-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Clofarabine Other / unclassified 2 mg/m2